Skip to main content

Table 1 Clinical characteristics of the studied cohort (n = 66)

From: Germline TP53 and MSH6 mutations implicated in sporadic triple-negative breast cancer (TNBC): a preliminary study

Characteristics

Values (n = 66 patients)

Age at diagnosis (years)

 Median, range

51.5, 30–91

Stage

 I

13 (19.7%)

 II

39 (59.1%)

 III

12 (18.2%)

 Undetermined

2 (3.0%)

BRCA germline status (Sanger sequencing confirmed)

 BRCA1 carrier

5 (7.6%)

 BRCA2 carrier

2 (3.0%)

 BRCA-negative

59 (89.4%)

Progression status

 PFS

53 (80.3%)

 Relapse/metastasis

6 (9.1%)

 Death

1 (1.5%)

 Undetermined

6 (9.1%)

Whether (or not) treated with neoadjuvant therapy

 Yes

7 (10.6%)

 No

55 (83.3%)

 Undetermined

4 (6.1%)

Chemotherapy regimen

 TEC

16 (24.2%)

 EC-T

20 (30.3%)

 TC

3 (4.5%)

 Other

10 (15.2%)

 None

17 (25.8%)

  1. Abbreviations: PFS progression-free survival, TEC docetaxel-epirubicin-cyclophosphamide, EC-T epirubicin-cyclophosphamide followed by docetaxel, TC docetaxel-cyclophosphamide